Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19Articles Published on 2020-10-142022-10-28 Journal: The American Journal of Tropical Medicine and Hygi [Category] COVID-19, MERS, SARS, [키워드] Bacterial Corticosteroid COVID-19 patient Endemic fungal global pandemic High-dose immunosuppressive individuals with COVID-19 Infection Region SARS-CoV-2 virus Screening strongyloidiasis therapy Tocilizumab Treatment with COVID-19 [DOI] 10.4269/ajtmh.20-0699 PMC 바로가기 [Article Type] Articles
Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case seriesCase Report Published on 2020-10-132022-11-01 Journal: Clinical Case Reports [Category] COVID-19, [키워드] acute respiratory distress acute respiratory distress syndrome antiviral therapy case sery clinical trials Combination COVID‐19 COVID‐19 diagnosed died Favipiravir Hydroxychloroquine Patient Pneumonia progressed Ritonavir survived syndrome the disease Tocilizumab Treatment Two patient [DOI] 10.1002/ccr3.3407 PMC 바로가기 [Article Type] Case Report
Lack of tocilizumab effect on mortality in COVID19 patientsArticle Published on 2020-10-132022-10-04 Journal: Scientific Reports [Category] Coronavirus, MERS, SARS, 바이오마커, [키워드] alterations clinical trial correlated COVID-19 patient COVID-19 pneumonia patient COVID19 patient Cytokine release syndrome Diseases elevated IL-6 IL-6 level lack Mortality Outcomes research reflect Tocilizumab tocilizumab administration [DOI] 10.1038/s41598-020-74328-x PMC 바로가기 [Article Type] Article
Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current EvidenceInternal Medicine Published on 2020-10-092022-10-31 Journal: Cureus [Category] COVID-19, [키워드] 95% confidence interval Abstract analyses Analysis anti-IL-6 article articles baseline characteristics biologic agent calculated case-control study collaboration college control arm control group coronavirus disease COVID-19 COVID-19 patients Critical Critically ill current database demonstrated Denmark Efficacy elevated Endpoint Health IL-6 Immunological response Infection intensive care interleukin-6 invasive ventilation material mean difference Meta-analysis Mortality observational studies outcome oxygen saturation Patient patients with COVID-19 pharmacological treatment positive random effect model reducing mortality regimen reported Result review risk risk ratio Safe Safety SARS-CoV-2 searched Seven severe COVID-19 significant difference significantly lower standard care group Stata Corporation Station suggested systematic review Tocilizumab tocilizumab patient treatment with tocilizumab were used [DOI] 10.7759/cureus.10869 PMC 바로가기 [Article Type] Internal Medicine
Preemptive interleukin-6 blockade in patients with COVID-19Article Published on 2020-10-082022-10-04 Journal: Scientific Reports [Category] MERS, SARS, 바이오마커, 치료제, [키워드] antibody anticipated Biological blockade C-reactive protein catastrophic clinical manifestation clinical marker collected Comorbidity consequence contributing to COVID-19 criteria Cytokine release syndrome Cytokine storm D-dimer death disease evaluated Final Gender Health care humanized implicated In-hospital inclusion criteria Infectious diseases initial interleukin-6 key factor monoclonal Nasopharyngeal swab nasopharynx non-responder outcome outcomes Patient patients patients hospitalized patients with COVID-19 plasma biomarker predicted predictor predictors Prevent profile receptor Responder Safe severely ill patients Signaling SOFA SOFA score Stage Systolic blood pressure Temporal the SARS-CoV-2 therapy Tocilizumab treated with COVID-19 [DOI] 10.1038/s41598-020-74001-3 PMC 바로가기 [Article Type] Article
Outlook of IL-6 signaling blockade for COVID-19 pneumoniaReview Published on 2020-10-052022-10-30 Journal: Inflammation and Regeneration [Category] COVID-19, [키워드] blockade Combination COVID-19 COVID-19 pneumonia Cytokine release syndrome disease Efficacy function Hospitalized hospitalized patient IL-6 IL-6 signaling implication inflammatory condition inhibitor inhibitors interleukin-6 physiological placebo-controlled study pleiotropic Pneumonia Population Randomized real-world data sarilumab Severe COVID-19 pneumonia siltuximab Standard of care therapeutic option Tocilizumab treat Treatment treatment for COVID-19 Trial unmet need [DOI] 10.1186/s41232-020-00134-7 PMC 바로가기 [Article Type] Review
Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-AnalysisMedicine Published on 2020-10-022022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 95% CI abstracts addition antibody article benefit Combination coronavirus (2019-nCoV) COVID-19 database death rate Efficacy eligible Evidence heterogeneity inconsistency index initial males Meta-analysis Odds ratio Patient performed randomized clinical trial reduce mortality reducing mortality Retrospective study review SARS-C0V-2 infection severe coronavirus disease severe COVID-19 Standard Standard of care statistical analysis systematic review TCZ Tocilizumab tocilizumab (IL-6 inhibitor) tocilizumab (TCZ) Treatment was done was performed were excluded were used [DOI] 10.3389/fmed.2020.586221 PMC 바로가기 [Article Type] Medicine
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysisComparative Study Published on 2020-10-012023-07-06 Journal: The Journal of Infection [Category] SARS, [키워드] COVID-19 IL-6 Orotracheal tube SARS-CoV2 Tocilizumab [DOI] 10.1016/j.jinf.2020.07.008 PMC 바로가기 [Article Type] Comparative Study
Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital NetworkObservational Study Published on 2020-10-012022-10-05 Journal: Hepatology (Baltimore, Md.) [Category] SARS, 임상, [키워드] abnormality acute respiratory distress acute respiratory syndrome Admission age alanine aminotransferase albumin alkaline phosphatase ALP ALT analyzed Aspartate aminotransferase association AST baseline body mass index caused Characteristics clinical Clinical outcome clinical outcomes conducted coronavirus COVID-19 death Diabetes Mellitus disease Elevation Hospitalization Hospitalized hospitalized patient Hydroxychloroquine ICU admission Injury intensive care limit liver liver test liver transaminase Major Male sex mechanical ventilation morbidity and mortality Most patient multiorgan failure Multivariate analysis network occur outcome pandemic Patient Pneumonia proportion Remdesivir reported retrospective cohort study severe COVID-19 syndrome System Test Tocilizumab total bilirubin Treatment ULN virus with COVID-19 [DOI] 10.1002/hep.31487 PMC 바로가기 [Article Type] Observational Study
Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patientsArticle Published on 2020-10-012023-07-06 Journal: International Journal of Infectious Diseases [Category] SARS, [키워드] COVID-19 Invasive mechanical ventilation Mortality SARS-CoV-2 Tocilizumab [DOI] 10.1016/j.ijid.2020.08.024 PMC 바로가기